These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation. Pelletier RP, Rajab AA, Diez A, DiPaola NR, Bumgardner GL, Elkhammas EA, Henry ML. Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932 [Abstract] [Full Text] [Related]
30. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation. Vo AA, Aubert O, Haas M, Huang E, Zhang X, Choi J, Peng A, Najjar R, Sethi S, Ammerman N, Lim K, Jordan SC. Transplantation; 2019 Dec 27; 103(12):2666-2674. PubMed ID: 30883456 [Abstract] [Full Text] [Related]
31. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Cooper JE, Gralla J, Chan L, Wiseman AC. Clin Transpl; 2011 Dec 27; ():359-64. PubMed ID: 22755431 [Abstract] [Full Text] [Related]
32. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Ntokou IS, Iniotaki AG, Kontou EN, Darema MN, Apostolaki MD, Kostakis AG, Boletis JN. Transpl Int; 2011 Nov 27; 24(11):1084-93. PubMed ID: 21848902 [Abstract] [Full Text] [Related]